HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

JNJ

Johnson & Johnson (Dow Jones 30, S&P 500)

Healthcare — Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Buy 1.9 / 5 22 analysts
$266.73
+$0.78 (+0.29%)
Target: $270.59 (1.4%)
Sign in to add JNJ to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$642.79B
P/E Ratio (TTM)30.94
Forward P/E20.79
EPS (TTM)$8.62
Dividend Yield2.02%
Profit Margin21.48%
Revenue Growth6.60%
ROE25.74%
Debt/Equity57.71
Recommendation Buy 1.9
Analyst Target$270.59
Analysts22
Indexes Dow Jones 30 S&P 500

Technical Indicators

RSI (14)53.6
Beta0.24
SMA 20$257.46
SMA 40$246.73
52-Week High$274.89
52-Week Low$164.23
50-Day Avg$242.64
200-Day Avg$225.02
Avg Volume$8.25M
Volume$10.39M

Performance Analysis

BULLISH

JNJ shows predominantly bullish signals based on its fundamentals and technicals.

- Trading near its 52-week high ($274.89), which may indicate limited upside.
~ RSI at 53.6 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 6.6% year-over-year.
+ Healthy profit margin of 21.5%.
+ Wall Street consensus is "Buy" from 22 analysts.
+ Average analyst target of $270.59 implies 1.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report